Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Interest Expenses (2016 - 2025)

Enanta Pharmaceuticals' Interest Expenses history spans 9 years, with the latest figure at $3.1 million for Q4 2025.

  • For Q4 2025, Interest Expenses rose 57.14% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $8.8 million, down 6.97%, while the annual FY2025 figure was $7.7 million, 29.79% down from the prior year.
  • Interest Expenses reached $3.1 million in Q4 2025 per ENTA's latest filing, up from $2.4 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $3.4 million in Q4 2023 to a low of $1.6 million in Q2 2025.
  • Average Interest Expenses over 3 years is $2.4 million, with a median of $2.4 million recorded in 2025.
  • Peak YoY movement for Interest Expenses: crashed 42.98% in 2024, then surged 57.14% in 2025.
  • A 3-year view of Interest Expenses shows it stood at $3.4 million in 2023, then plummeted by 42.98% to $2.0 million in 2024, then surged by 57.14% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Interest Expenses are $3.1 million (Q4 2025), $2.4 million (Q3 2025), and $1.6 million (Q2 2025).